References
- Chang, K. C., Leung, C. C., Yew, W. W., Lau, T. Y., Tam, C. M. (2008). Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 177:1391–1396.
- Horsfall, P. A., Plummer, J., Allan, W. G., Girling, D. J., Nunn, A. J., Fox, W. (1979). Double-blind, controlled comparison of aspirin, allopurinol, and placebo in the management of arthralgia during pyrazinamide administration. Tubercle 60:13–24.
- Jasmer, R. M., Daley, C. L. (2003). Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med 167:809–810.
- Knowles, S. R., Uetrecht, J., Shear, N. H. (2000). Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 356:1587–1591.
- Lacroix, C., Guyonnaud, C., Chaou, M., Duwoos, H., Lafont, O. (1988). Interaction between allopurinol and pyrazinamide. Eur Respir J 1:807–811.
- Lacroix, C., Hoang, T. P., Nouveau, J., Guyonnaud, C., Laine, G., Duwoos, H., et al. (1989). Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 36:395–400.
- Lee, Y. S., Kang, Y. S., Lee, S. H., Kim, J. A. (2000). Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 7:925–932.
- Roy, S. K., Korzekwa, K. R., Gonzalez, F. J., Moschel, R. C., Dolan, M. E. (1995). Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol 50:1385–1389.
- Tostmann, A., Boeree, M. J., Aarnoutse, R. E., de Lange, W. C., van der Ven, A. J., Dekhuijzen, R. (2008). Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23:192–202.
- Weiner, I. M., Tinker, J. P. (1972). Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention. J Pharmacol Exp Ther 180:411–434.
- Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., Menzies, D. (2003). Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472–1477.
- Younossian, A. B., Rochat, T., Ketterer, J. P., Wacker, J., Janssens, J. P. (2005). High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 26:462–464.